On June 9, 2025, Jan Janisch-Hanzlik sat down for an infusion at the University of Nebraska Medical Center in Omaha that could rewrite her future. At 49, the nurse from Blair, Nebraska, had watched multiple sclerosis systematically dismantle her independence: she'd left her active nursing career for a desk job, grew afraid to carry her grandchildren after frequent falls, and moved to a larger house to accommodate the wheelchair she feared she might need full-time. When even the best available medications failed to slow her decline, she began calling the clinic every other month, determined to enroll in a clinical trial that seemed impossible just years ago—using a cancer therapy to reset her broken immune system.
CAR T cell therapy, first approved by the FDA in 2017 to treat aggressive leukemia, has delivered long-term remission for many cancer patients by reprogramming their own immune cells to hunt and destroy malignant cells. The mechanics are elegant: scientists extract a patient's T cells, insert genetic instructions for a "chimeric antigen receptor" that helps the cells recognize cancer, and return them to the bloodstream as precision killers. The therapy works by targeting B cells, immune players that go haywire in certain cancers by multiplying out of control. But B cells also sit at the heart of autoimmune disease—the difference is that they mistakenly attack healthy tissue instead of invading pathogens. When CAR T began proving its power against B cell cancers, the logic for autoimmunity became irresistible: what if the same approach could eliminate the rogue B cells in multiple sclerosis, lupus, Graves' disease, and vasculitis?
That reasoning has now materialized into hundreds of clinical trials across the world, making Janisch-Hanzlik the first patient at her institution to test whether CAR T can essentially reset the body's defenses to a state before disease took hold. The promise is genuine, but so is the uncertainty. Researchers still don't know how durable the benefits will be or what long-term side effects might emerge. When Janisch-Hanzlik received her infusion, she knew she'd spend the following week hospitalized and monitored for dangerous inflammation and other serious complications. Yet she chose to accept those risks—partly because of her clinical expertise as a nurse, partly because of two young grandchildren who carry an elevated genetic risk for the same disease. "I would want to be able to say I did everything that I possibly could to prevent them, or anyone else, from having something like this," she said.
What makes this moment significant is not just one woman's courage, but a fundamental shift in how medicine thinks about immune-system breakdown. For decades, autoimmune diseases were treated by suppressing immunity broadly—a blunt instrument that left patients vulnerable to infection. CAR T represents something different: surgical precision, a way to target and eliminate only the cells causing harm while leaving the rest of the immune system intact. The risks remain real, and the long-term data are sparse. But at the University of Nebraska Medical Center and in hundreds of clinics worldwide, patients are now answering the same question Janisch-Hanzlik did: what if we could stop the disease instead of just managing it?